Autosomal Recessive Spinocerebellar Ataxia 20 (SCAR20): Disease-Characteristics Report

Scope and evidence date. This report emphasizes primary human and experimental evidence available through 2024. SCAR20 is exceptionally rare; consequently, many clinical estimates derive from small, partly overlapping cohorts rather than population registries. Statements labeled unknown should not be interpreted as evidence of absence.

Executive summary

Autosomal recessive spinocerebellar ataxia 20 (SCAR20) is a childhood-onset syndromic neurodevelopmental and neurodegenerative disorder caused by biallelic loss-of-function or function-reducing variants in SNX14. The defining phenotype combines global developmental delay or severe intellectual disability, markedly limited or absent speech, congenital/early hypotonia, gait ataxia, progressive cerebellar atrophy, relative macrocephaly, and recognizable coarse facial features. In the principal 22-person cohort, delayed motor development, delayed/absent language and social development, hypotonia, gait abnormality, cerebellar atrophy, and coarse facies were each reported in 22/22 individuals; seizures occurred in 8/22 and autistic-like behavior in 12/22. (akizu2015biallelicmutationsin pages 21-23)

Current mechanistic evidence converges on defective lipid handling at endoplasmic-reticulum (ER)–lipid-droplet and lysosomal interfaces, impaired fatty-acid desaturation and storage, and disturbed microtubule-dependent mitochondrial transport. Cerebellar Purkinje cells are selectively vulnerable. A 2024 mouse study found cerebellum-specific acylcarnitine accumulation, reduced triglyceride species, fewer lipid droplets, and enlarged telolysosomes before overt Purkinje-cell degeneration. No disease-modifying human treatment or SCAR20-specific interventional trial has been established; valproate and SCD1-directed rescue remain preclinical findings. (zhou2024alteredlipidhomeostasis pages 1-2, zhou2024alteredlipidhomeostasis pages 9-12, zhou2024alteredlipidhomeostasis pages 12-13)

Table: This table summarizes the strongest currently gathered evidence for SNX14-related autosomal recessive spinocerebellar ataxia 20 across clinical, mechanistic, diagnostic, and model-system domains. It is designed to help populate a structured knowledge base while clearly separating human-established findings from mouse-only preclinical results.

1. Disease information

Definition and identifiers

SCAR20 is a Mendelian, autosomal-recessive, syndromic cerebellar ataxia caused by biallelic pathogenic variants in SNX14, encoding sorting nexin 14. It combines impaired neurodevelopment with progressive cerebellar degeneration rather than representing an isolated adult-onset ataxia. Open Targets links SNX14 (Ensembl ENSG00000135317) to SCAR20 with five supporting evidence records, including expert-panel and human-genetic evidence. (OpenTargets Search: autosomal recessive spinocerebellar ataxia 20-SNX14)

• MONDO: MONDO:0014601
• OMIM phenotype: 616354
• Gene: SNX14, sorting nexin 14; Ensembl ENSG00000135317
• Common names: SCAR20; autosomal recessive spinocerebellar ataxia type 20; SNX14-related cerebellar ataxia; SNX14-related cerebellar atrophy–intellectual disability syndrome; syndromic cerebellar atrophy and lysosome-autophagosome dysfunction.
• Orphanet: a stable disease-specific Orphanet identifier was not established in the retrieved evidence.
• ICD-10/ICD-11: no unique SCAR20 code was identified; clinically it is generally represented under hereditary ataxia/cerebellar-degeneration categories.
• MeSH: no disease-specific MeSH descriptor was identified; broader terms include Spinocerebellar Ataxias and Cerebellar Atrophy.

The evidence is principally aggregated disease-level literature and curated genetic resources, underpinned by individually phenotyped families. It is not derived from large electronic-health-record cohorts.

Important nomenclature caution: the correct OMIM number is 616354. One 2023 article’s introductory text was rendered as “MIM:216354” in an extracted passage, but the established identifier in the broader literature is 616354. (kim2021twokoreansiblings pages 1-3, levchenko2023homozygousdeepintronic pages 1-2, bryant2018snx14mutationsaffect pages 1-2)

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The necessary causal factor is biallelic germline SNX14 dysfunction. Most established alleles are nonsense, frameshift, canonical splice, exon-level deletion, or complex structural variants expected to cause absent/truncated protein or nonsense-mediated decay. Missense alleles require especially careful functional and segregation evidence because loss of SNX14 is the best-supported disease mechanism. (levchenko2023homozygousdeepintronic pages 1-2, bryant2018snx14mutationsaffect pages 1-2, kim2021twokoreansiblings pages 4-5)

Recent examples include:

• Homozygous c.462-589A>G, a deep-intronic allele that inserts an 82-nt pseudo-exon and generates p.Asp155Valfs*8; trio WGS and RNA analysis were required (Frontiers in Genetics, 25 July 2023; DOI: https://doi.org/10.3389/fgene.2023.1197681; PMID 37485342). (levchenko2023homozygousdeepintronic pages 1-2)
• Compound heterozygosity for c.712A>T (p.Arg238Ter), classified pathogenic, and c.2744A>T (p.Gln915Leu), classified VUS under ACMG criteria; both reduced SNX14 expression in vitro (Frontiers in Genetics, 9 April 2024; DOI: https://doi.org/10.3389/fgene.2024.1379366; PMID 38655056). The VUS should not be represented as independently proven pathogenic. (shao2024compoundheterozygousmutation pages 1-2)
• Homozygous c.2746-2A>G, predicted to disrupt splicing and cause loss of function, in two Korean siblings. (kim2021twokoreansiblings pages 1-3)
• p.Arg399Ter in trans with a complex deletion–inversion–insertion rearrangement in the first reported non-consanguineous compound-heterozygous family. (maia2020twocompoundheterozygous pages 1-2)

Risk factors

• Genetic: two pathogenic SNX14 alleles; parental carrier status; consanguinity; and family history of a compatible recessive neurodevelopmental syndrome.
• Recurrence: when both parents are confirmed heterozygous carriers, each pregnancy has a 25% affected, 50% carrier, and 25% unaffected/non-carrier probability, assuming no unusual mosaicism or uniparental mechanism.
• Environmental, infectious, toxic, occupational, lifestyle, age, and sex risks: none are established as causes or susceptibility factors.
• Modifier genes: none validated.
• Protective alleles: none validated.
• Epigenetic modifiers: no disease-specific methylation or chromatin signature has been established.

Experimental saturated-fatty-acid exposure intensifies ER stress/toxicity in SNX14-deficient cells, whereas oleate is used experimentally to stimulate lipid droplets. This demonstrates cellular context sensitivity, not a proven dietary gene–environment interaction in patients. No evidence currently supports prescribing a particular fat intake to alter human SCAR20. (zhou2024alteredlipidhomeostasis pages 1-2, bryant2018snx14mutationsaffect pages 1-2)

3. Phenotypes

The best quantitative estimates come from the 22-person discovery/expansion cohort and should be treated as approximate because ascertainment favored recognizable severe cases. (akizu2015biallelicmutationsin pages 21-23)

Characteristic facial findings include prominent/high forehead, telecanthus or epicanthal folds, depressed/broad nasal bridge and base, upturned nares, long/broad philtrum, and full/thick lips. (kim2021twokoreansiblings pages 1-3, akizu2015biallelicmutationsin pages 4-6, akizu2015biallelicmutationsin pages 21-23)

MRI findings beyond cerebellar atrophy include delayed myelination, thin corpus callosum, prominent extra-axial fluid, occasional periventricular white-matter injury, and pontine atrophy. A Korean sibling had a normal-appearing cerebellum at age two while the older sibling developed clear progressive atrophy between ages two and four, showing that an early normal MRI does not exclude SCAR20. Routine metabolic investigations have generally been unrevealing. (kim2021twokoreansiblings pages 1-3, kim2021twokoreansiblings pages 3-4, maia2020twocompoundheterozygous pages 1-2)

No SCAR20-specific EQ-5D, SF-36, PROMIS, or validated quality-of-life dataset was found. Nevertheless, severe communication impairment, dependence for mobility and self-care, seizures, hearing impairment, and orthopedic complications imply substantial patient and caregiver burden.

4. Genetic and molecular information

Gene and variant architecture

SNX14 is the sole established SCAR20 gene. The Open Targets association is supported by human genetics and a Cerebellar Ataxia Gene Curation Expert Panel. (OpenTargets Search: autosomal recessive spinocerebellar ataxia 20-SNX14)

Reported disease alleles encompass:

• nonsense and frameshift variants;
• canonical and deep-intronic splice variants;
• exon/gene deletions;
• complex rearrangements containing deletions, inversion, and insertion;
• rare missense variants with uncertain or function-reducing evidence.

All are germline in reported families; no somatic SCAR20 mechanism is known. The dominant functional consequence is loss of function, not gain of function or dominant negative action. By 2018, at least 45 affected individuals from 24 families and 18 distinct point mutations/deletions had been described; by 2020, at least 47 individuals from 25 consanguineous families and 19 homozygous pathogenic alleles were cited. A 2021 report counted 19 homozygous and two compound-heterozygous pathogenic genotypes. These counts overlap and are historical snapshots, not prevalence estimates. (bryant2018snx14mutationsaffect pages 1-2, kim2021twokoreansiblings pages 4-5, maia2020twocompoundheterozygous pages 1-2)

Population allele frequencies were not consistently available in the retrieved primary texts. For a severe ultra-rare recessive condition, confidently pathogenic alleles are expected to be absent or extremely rare in gnomAD, but each candidate must be checked against the current transcript/build and ancestry-specific dataset. No validated founder allele or reliable human carrier-frequency estimate is established from the gathered literature.

There is no evidence for recurrent aneuploidy, translocation, anticipation, or a disease-specific epigenetic abnormality. Germline mosaicism has not been demonstrated, although low residual recurrence risk after an apparently de novo parental-negative result is a general counseling consideration.

5. Environmental information

No toxin, radiation, pollution, occupation, smoking, alcohol, diet, exercise pattern, or infectious organism is known to cause SCAR20. The disorder is not infectious or transmissible. Saturated-fatty-acid sensitivity in cultured SNX14-deficient cells is mechanistically informative but cannot currently be translated into a human dietary recommendation. (zhou2024alteredlipidhomeostasis pages 1-2)

6. Mechanism and pathophysiology

Integrated causal chain

1. Upstream trigger: biallelic SNX14 loss reduces or eliminates functional SNX14 protein.
2. Organelle-interface dysfunction: SNX14 normally associates with the ER and ER–lipid-droplet contacts and participates in non-vesicular lipid handling, lipid-droplet growth, and fatty-acid desaturation in functional cooperation with SCD1. N-terminal transmembrane helices are required for ER localization; the PX domain was dispensable in one cell study. (zhou2024alteredlipidhomeostasis pages 1-2, bryant2018snx14mutationsaffect pages 1-2)
3. Lipid-storage/clearance defect: deficient cells accumulate saturated lipids, show impaired neutral-lipid storage and lipid-droplet biogenesis, abnormal lysosomal cholesterol distribution, enlarged lysosomes, and altered autophagy. (zhou2024alteredlipidhomeostasis pages 1-2, bryant2018snx14mutationsaffect pages 1-2)
4. Transport/energy defect: mouse evidence indicates SNX14 interacts with and stabilizes spastin, supporting microtubule organization and axonal mitochondrial transport. Deficiency compromises mitochondrial delivery/function in long Purkinje-cell axons. (zhang2021snx14deficiencyinduceddefective pages 8-9, zhang2021snx14deficiencyinduceddefective pages 12-12)
5. Selective cellular vulnerability: high-energy-demanding Purkinje cells develop lipid-storage stress, enlarged telolysosomes, later ER swelling and mitochondrial damage, and ultimately cell-autonomous degeneration.
6. Tissue and clinical outcome: progressive cerebellar cortical loss produces ataxia, impaired coordination, and cerebellar atrophy; developmental effects and possibly broader lysosome/autophagy dysfunction contribute to intellectual disability, absent speech, autism-like behavior, and systemic features.

2024 molecular profiling

In two-month-old, predegenerating Snx14-knockout mice, lipidomics using n=8 wild-type and n=10 knockout animals found significantly increased total acylcarnitines specifically in cerebellum. MALDI mass-spectrometry imaging showed cerebellar depletion of PE C38:2, TG 46:1, and TG 53:2 and accumulation of L-carnitine. Snx14-deficient Purkinje cells formed approximately half as many oleate-induced lipid droplets as controls. TEM showed fewer but enlarged telolysosomes, while predegenerating mitochondria remained mostly intact—supporting lipid storage/clearance failure as an early lesion rather than merely a consequence of mitochondrial destruction. RNA-seq data are deposited as GEO GSE215834. (zhou2024alteredlipidhomeostasis pages 9-12, zhou2024alteredlipidhomeostasis pages 17-18)

The corresponding figure directly demonstrates tissue-selective acylcarnitine elevation and triglyceride/phosphatidylethanolamine changes, followed by fewer lipid droplets, enlarged telolysosomes, and a morphological gradient of Purkinje-cell degeneration. (zhou2024alteredlipidhomeostasis media 516308f2, zhou2024alteredlipidhomeostasis media 2328fed7, zhou2024alteredlipidhomeostasis media 36ea72c9, zhou2024alteredlipidhomeostasis media 6cd7fcc8, zhou2024alteredlipidhomeostasis media 28783b99)

Suggested ontology annotations

• GO biological process: lipid transport (GO:0006869); fatty-acid metabolic process (GO:0006631); lipid-droplet organization (GO:0034389); macroautophagy (GO:0016236); microtubule-based movement (GO:0007018); mitochondrial transport along microtubule (more specific descendant where supported); neuron death (GO:0070997).
• GO cellular component: ER (GO:0005783); lipid droplet (GO:0005811); lysosome (GO:0005764); mitochondrion (GO:0005739); microtubule cytoskeleton (GO:0015630).
• Cell Ontology: Purkinje cell (CL:0000121); neuron (CL:0000540). Direct disease evidence is strongest for Purkinje cells.
• CHEBI concepts: saturated fatty acid; oleic acid; acylcarnitine; L-carnitine; triacylglycerol; phosphatidylethanolamine; cholesterol ester.

No replicated human single-cell, spatial-transcriptomic, proteomic, lipidomic, or metabolomic biomarker study was found. The detailed profiling above is from mice, not patient biofluids.

7. Anatomical structures affected

The primary organ is the central nervous system, especially the cerebellum (UBERON:0002037), cerebellar cortex, vermis and hemispheres. The principal vulnerable cell is the Purkinje neuron (CL:0000121), with its dendrites and long axon. Pontine and cerebral white-matter/corpus-callosum abnormalities occur in some patients but are less consistent. Degeneration appears bilateral/diffuse rather than characteristically lateralized. (kim2021twokoreansiblings pages 1-3, maia2020twocompoundheterozygous pages 1-2, zhou2024alteredlipidhomeostasis pages 1-2)

At the subcellular level, implicated compartments are the ER, lipid droplets, lysosomes/telolysosomes, autophagosomes, microtubules, axons, and mitochondria. Secondary systemic findings can include hearing apparatus involvement, skeleton, liver and spleen, but there is no established progressive primary hepatic storage disease. (akizu2015biallelicmutationsin pages 4-6, akizu2015biallelicmutationsin pages 21-23)

8. Temporal development

Onset is usually congenital or infantile, often beginning with hypotonia and delayed motor milestones. One family showed hypotonia and absent head control by three months; another report documented sitting at 11 months, an ataxic gait at 18 months, and first words at two years. (levchenko2023homozygousdeepintronic pages 1-2, maia2020twocompoundheterozygous pages 1-2)

The course is chronic and lifelong. Neurodevelopmental impairment is early and usually severe, while cerebellar atrophy and ataxia can be progressive. MRI may lag behind clinical abnormalities. There are no validated disease stages, annualized progression rates, remission patterns, or intervention windows in humans. A rational—but unproven—therapeutic window would precede extensive Purkinje-cell loss, because mouse lipid abnormalities and telolysosomal enlargement are present at “predegenerating” ages. (zhou2024alteredlipidhomeostasis pages 9-12)

9. Inheritance and population

Inheritance is autosomal recessive. Affected individuals may be homozygous, often in consanguineous families, or compound heterozygous. The first reported non-consanguineous compound-heterozygous family broadened the recognized architecture. (maia2020twocompoundheterozygous pages 1-2)

• Penetrance: apparently high for clearly biallelic loss-of-function genotypes in reported families, but no unbiased age-specific penetrance estimate exists.
• Expressivity: variable, particularly for walking ability, seizures, hearing loss, skeletal manifestations, autism-like behavior, and MRI timing.
• Anticipation: not expected and not reported; SCAR20 is not a repeat-expansion disorder.
• Sex ratio: no reliable estimate and no evidence for sex-linked risk.
• Founder effects/geographic distribution: reports span Middle Eastern, North African, Turkish, Portuguese, Indian, Korean, Russian and other families, but no global geographic prevalence can be calculated from case reports.
• Incidence/prevalence: unknown; no population-based numerator or denominator is available.
• Carrier frequency: unknown for humans.

Consanguinity is a major ascertainment and reproductive-risk factor but is not required. In the 2023 deep-intronic family and many earlier families, homozygosity was facilitated by parental relatedness. (levchenko2023homozygousdeepintronic pages 1-2, maia2020twocompoundheterozygous pages 1-2)

10. Diagnostics

Clinical suspicion and baseline assessment

Suspect SCAR20 in a child with severe global developmental delay/intellectual disability, congenital hypotonia, minimal or absent speech, progressive gait ataxia, cerebellar atrophy, relative macrocephaly, and coarse facial features. Hearing loss, seizures, skeletal abnormalities, hypertrichosis, macroglossia, or hepatosplenomegaly provide additional support. (kim2021twokoreansiblings pages 3-4, akizu2015biallelicmutationsin pages 21-23)

Recommended clinical evaluation includes:

• neurologic and developmental examination, including gait and movement-disorder assessment;
• brain MRI with attention to cerebellar hemispheres/vermis, pons, corpus callosum and myelination;
• formal hearing and vision/oculomotor assessment;
• EEG when seizures are suspected;
• feeding/swallowing, nutrition, orthopedic and rehabilitation assessments;
• routine metabolic testing principally to exclude treatable mimics; no diagnostic biochemical marker is established.

No disease-specific diagnostic clinical criteria, enzyme assay, blood/urine biomarker, electrophysiologic signature, or biopsy criterion exists.

Genetic testing algorithm

1. Use a comprehensive childhood-onset ataxia/neurodevelopmental panel that includes SNX14, or trio WES when the phenotype is heterogeneous.
2. Confirm candidate variants and phase by parental testing/Sanger sequencing; evaluate CNVs and exon-level deletions.
3. If WES is negative but suspicion remains high, perform WGS, because deep-intronic and complex structural alleles may be missed.
4. Perform RNA studies from an informative tissue/cell type to confirm suspected splice effects or pseudo-exon inclusion.
5. Interpret missense variants under ACMG/AMP criteria and avoid converting a VUS into a diagnostic allele without segregation and functional support.

The 2023 report is a strong demonstration of WGS utility: trio WGS found c.462-589A>G after an extensive negative diagnostic search, and RNA analysis established pseudo-exon inclusion. (levchenko2023homozygousdeepintronic pages 1-2)

CMA can detect a large deletion but will miss most sequence alleles; karyotyping and FISH are not first-line. Repeat-expansion and mitochondrial-DNA testing do not diagnose SCAR20, although they may be part of a broad ataxia differential. Prenatal and preimplantation testing become technically feasible once familial pathogenic variants are known.

Differential diagnosis

Differentials include other syndromic recessive ataxias and congenital cerebellar disorders, particularly PNKP-, PMPCA-, EXOSC3-, COQ8A/ADCK3-, SETX-, VPS13D-, PTF1A-, ATCAY-, GRID2-, and SEPSECS-related conditions; lysosomal/autophagy disorders; congenital disorders of glycosylation; mitochondrial disease; and treatable causes such as coenzyme-Q deficiency and vitamin E deficiency. Coarse facies and hepatosplenomegaly can suggest mucopolysaccharidosis, but routine metabolic studies in SCAR20 are generally normal and molecular testing is decisive. (kim2021twokoreansiblings pages 3-4, akizu2015biallelicmutationsin pages 4-6)

11. Outcome and prognosis

SCAR20 causes substantial, usually lifelong disability. Many patients have severe intellectual and communication impairment; some never achieve independent walking or functional speech. Progressive cerebellar degeneration may worsen coordination after an initially developmental presentation. Seizures, hearing loss, dysphagia/nutritional difficulty, falls, contractures, spinal deformity, and loss of mobility are plausible or reported morbidity drivers. (kim2021twokoreansiblings pages 1-3, maia2020twocompoundheterozygous pages 1-2, akizu2015biallelicmutationsin pages 21-23)

No reliable survival curve, life-expectancy estimate, mortality rate, disease-specific cause-of-death profile, recovery rate, or validated prognostic biomarker exists. Published children and young adults demonstrate survival beyond infancy, but available reports are too small and short to infer normal life expectancy. Genotype–severity correlations remain unproven.

12. Treatment

Current clinical management

There is no approved disease-modifying pharmacotherapy. Management is multidisciplinary and symptom-directed:

• Physical therapy for balance, strength, contracture prevention, transfers and mobility aids.
• Occupational therapy and adaptive equipment for daily activities.
• Speech-language therapy, augmentative/alternative communication, and swallowing assessment.
• Standard antiseizure medication selected by seizure type when epilepsy occurs.
• Audiology and hearing devices when indicated.
• Nutrition/feeding support and aspiration-risk management.
• Orthopedic surveillance and treatment of scoliosis, talipes, contractures or chest-wall abnormalities.
• Behavioral/developmental and educational support.

Suggested NCIT intervention concepts include Supportive Care, Physical Therapy, Occupational Therapy, Speech Therapy, Assistive Device, Genetic Counseling, Magnetic Resonance Imaging, and phenotype-specific anticonvulsant treatment.

Experimental approaches

In SNX14-deficient mice, valproate improved motor deficits and cerebellar degeneration while restoring mitochondrial transport/function. Another mouse analysis described partial rescue of Purkinje-cell degeneration. In cells, SCD1 overexpression rescued aspects of SNX14-loss lipid dysfunction. Conversely, hydroxypropyl-β-cyclodextrin failed to rescue mouse cerebellar degeneration. These findings support pathway exploration but do not establish valproate, lipid supplementation, SCD1 manipulation, or cyclodextrin as effective or safe human SCAR20 treatments. (zhang2021snx14deficiencyinduceddefective pages 8-9, zhou2024alteredlipidhomeostasis pages 12-13, zhang2021snx14deficiencyinduceddefective pages 12-12)

No SCAR20-specific gene therapy, ASO, siRNA, CRISPR, cell therapy, immunotherapy, surgery, combination regimen, treatment-response statistic, or pharmacogenomic guideline was found. Targeted ClinicalTrials.gov searches identified no relevant SCAR20 interventional trial.

13. Prevention

Because SCAR20 is genetic, primary prevention is reproductive rather than behavioral:

• preconception carrier testing for the reproductive partner of a known carrier;
• cascade testing of at-risk adult relatives;
• genetic counseling with explicit 25% recurrence risk for carrier couples;
• prenatal diagnosis by chorionic-villus sampling or amniocentesis;
• preimplantation genetic testing for monogenic disease where available.

Secondary prevention consists of early molecular diagnosis and surveillance for hearing loss, seizures, feeding problems and orthopedic complications. Tertiary prevention consists of rehabilitation, fall prevention, communication support, nutrition and contracture management. There is no vaccine, newborn-screening program, prophylactic medication, or evidence-based lifestyle intervention for SCAR20.

14. Other species and natural disease

A naturally occurring SNX14-associated cerebellar cortical degeneration occurs in Hungarian Vizsla dogs (Canis lupus familiaris, NCBI Taxon 9615). Two affected full siblings from a litter of nine developed progressive hypermetric/dysmetric ataxia, truncal sway, intention tremor and absent menace responses from approximately three months. Histopathology showed primary Purkinje-neuron loss. WGS identified a splice-donor allele; RNA showed abnormal splicing and western blotting found no detectable SNX14 protein in affected cerebellum. Screening 133 unaffected Vizslas identified three heterozygous carriers. This is a natural recessive comparative model, not a zoonosis. (fenn2016genomesequencingreveals pages 1-2)

The canine disorder closely recapitulates progressive cerebellar ataxia and Purkinje-cell loss but does not reproduce the full human intellectual-disability/dysmorphism syndrome. No cross-species transmission or infectious susceptibility is involved.

15. Model organisms

• Mouse — Mus musculus (Taxon 10090): full-body, nervous-system conditional and Purkinje-cell-specific Snx14 knockout models show motor deficits, progressive cerebellar degeneration and cell-autonomous Purkinje-cell vulnerability. They enable lipidomics, ultrastructure, axonal-transport analysis and preclinical rescue. Limitations include uncertain correspondence to human cognitive/facial/systemic manifestations. (zhou2024alteredlipidhomeostasis pages 1-2, zhang2021snx14deficiencyinduceddefective pages 8-9, zhang2021snx14deficiencyinduceddefective pages 12-12)
• Zebrafish — Danio rerio (Taxon 7955): morpholino knockdown produced apoptosis, reduced neural/cerebellar tissue and Purkinje progenitors, plus excess autophagic vesicles. It supports developmental and high-throughput studies, although some stable mutants reportedly lack a clear locomotor phenotype, highlighting model/compensation limitations. (akizu2015biallelicmutationsin pages 4-6)
• Dog — Canis lupus familiaris (Taxon 9615): natural Hungarian Vizsla disease offers high face validity for Purkinje degeneration and progressive ataxia. (fenn2016genomesequencingreveals pages 1-2)
• Human patient fibroblasts and neural progenitor-like cells: demonstrate lysosomal enlargement, altered autophagy, cholesterol/neutral-lipid abnormalities and disease-relevant endogenous genotypes. They lack mature cerebellar circuitry. (zhou2024alteredlipidhomeostasis pages 1-2, bryant2018snx14mutationsaffect pages 1-2)
• Engineered HEK293 and related cell systems: useful for ER localization, lipid-droplet formation, SCD1 interaction and rescue studies, but non-neuronal context limits phenotypic inference.

Key primary publications and exact abstract statements

1. Akizu et al., Nature Genetics, April 2015, “Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction.” DOI: https://doi.org/10.1038/ng.3256; PMID 25848753. The title itself captures the authors’ central conclusion; the study supplied the principal 22-person clinical dataset and zebrafish/cellular evidence. (akizu2015biallelicmutationsin pages 4-6, akizu2015biallelicmutationsin pages 21-23)
2. Bryant et al., Human Molecular Genetics, 1 June 2018, DOI: https://doi.org/10.1093/hmg/ddy101. The paper concludes that SNX14 has “an important role … in neutral lipid homeostasis between the ER, lysosomes and LDs.” (bryant2018snx14mutationsaffect pages 1-2)
3. Zhang et al., National Science Review, February 2021, DOI: https://doi.org/10.1093/nsr/nwab024. Abstract: “Axonal transport disruption and mitochondrial dysfunction further led to degeneration of high-energy-demanding Purkinje cells.” The authors also reported that valproate ameliorated disease in mice, not humans. (zhang2021snx14deficiencyinduceddefective pages 8-9, zhang2021snx14deficiencyinduceddefective pages 12-12)
4. Levchenko et al., Frontiers in Genetics, 25 July 2023, DOI: https://doi.org/10.3389/fgene.2023.1197681; PMID 37485342. Abstract: “This variant resulted in the inclusion of a pseudo-exon 82 nucleotides long and the formation of a premature stop codon.” (levchenko2023homozygousdeepintronic pages 1-2)
5. Shao et al., Frontiers in Genetics, 9 April 2024, DOI: https://doi.org/10.3389/fgene.2024.1379366; PMID 38655056. Abstract: “In vitro experiments demonstrated that both variants reduced SNX14 expression.” (shao2024compoundheterozygousmutation pages 1-2)
6. Zhou et al., JCI Insight, April/May 2024, DOI: https://doi.org/10.1172/jci.insight.168594. Abstract: “Predegenerating SNX14-deficient cerebella show a unique accumulation of acylcarnitines and depletion of triglycerides,” and the authors propose lipotoxicity as a pathogenic mechanism. (zhou2024alteredlipidhomeostasis pages 1-2, zhou2024alteredlipidhomeostasis pages 9-12)

Evidence limitations and expert interpretation

The most secure conclusions are the biallelic SNX14 loss-of-function etiology, severe early neurodevelopmental syndrome, progressive cerebellar/Purkinje-cell pathology, and disrupted lipid-organelle homeostasis. Frequencies outside the original 22-person cohort, penetrance, epidemiology, survival, quality of life and genotype–phenotype relationships remain poorly quantified. The 2024 lipidomic work materially strengthens the lipid-dyshomeostasis model by demonstrating abnormalities before neuronal loss and by localizing them to the cerebellum, but it remains mouse evidence. Valproate is therefore a hypothesis-generating repurposing candidate, not a recommended SCAR20 therapy. The principal research priorities are prospective natural-history enrollment, standardized ataxia/developmental outcomes, patient-derived Purkinje-cell models, accessible lipid biomarkers, and intervention studies initiated before irreversible cerebellar degeneration.

References

1. (akizu2015biallelicmutationsin pages 21-23): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 110 citations and is from a highest quality peer-reviewed journal.

2. (zhou2024alteredlipidhomeostasis pages 1-2): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

3. (zhou2024alteredlipidhomeostasis pages 9-12): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

4. (zhou2024alteredlipidhomeostasis pages 12-13): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

5. (akizu2015biallelicmutationsin pages 4-6): Naiara Akizu, Vincent Cantagrel, Maha S Zaki, Lihadh Al-Gazali, Xin Wang, Rasim Ozgur Rosti, Esra Dikoglu, Antoinette Bernabe Gelot, Basak Rosti, Keith K Vaux, Eric M Scott, Jennifer L Silhavy, Jana Schroth, Brett Copeland, Ashleigh E Schaffer, Philip L S M Gordts, Jeffrey D Esko, Matthew D Buschman, Seth J Field, Gennaro Napolitano, Ghada M Abdel-Salam, R Koksal Ozgul, Mahmut Samil Sagıroglu, Matloob Azam, Samira Ismail, Mona Aglan, Laila Selim, Iman G Mahmoud, Sawsan Abdel-Hadi, Amera El Badawy, Abdelrahim A Sadek, Faezeh Mojahedi, Hulya Kayserili, Amira Masri, Laila Bastaki, Samia Temtamy, Ulrich Müller, Isabelle Desguerre, Jean-Laurent Casanova, Ali Dursun, Murat Gunel, Stacey B Gabriel, Pascale de Lonlay, and Joseph G Gleeson. Biallelic mutations in snx14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Apr 2015. URL: https://doi.org/10.1038/ng.3256, doi:10.1038/ng.3256. This article has 110 citations and is from a highest quality peer-reviewed journal.

6. (OpenTargets Search: autosomal recessive spinocerebellar ataxia 20-SNX14): Open Targets Query (autosomal recessive spinocerebellar ataxia 20-SNX14, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

7. (kim2021twokoreansiblings pages 1-3): Ae Ryoung Kim, Jong-Mok Lee, Go Hun Seo, Sang In Lee, Hyunwoo Bae, and Yun Jeong Lee. Two korean siblings with autosomal recessive spinocerebellar ataxia 20 caused by homozygous variants in snx14. Journal of Genetic Medicine, 18:127-131, Dec 2021. URL: https://doi.org/10.5734/jgm.2021.18.2.127, doi:10.5734/jgm.2021.18.2.127. This article has 1 citations.

8. (levchenko2023homozygousdeepintronic pages 1-2): Olga Levchenko, Alexandra Filatova, Irina Mishina, Aleksey Antonenko, and Mikhail Skoblov. Homozygous deep intronic variant in snx14 cause autosomal recessive spinocerebellar ataxia 20: a case report. Frontiers in Genetics, Jul 2023. URL: https://doi.org/10.3389/fgene.2023.1197681, doi:10.3389/fgene.2023.1197681. This article has 5 citations and is from a peer-reviewed journal.

9. (maia2020twocompoundheterozygous pages 1-2): Nuno Maia, Gabriela Soares, Cecília Silva, Isabel Marques, Bárbara Rodrigues, Rosário Santos, Manuel Melo-Pires, Arjan PM de Brouwer, Teresa Temudo, and Paula Jorge. Two compound heterozygous variants in snx14 cause stereotypies and dystonia in autosomal recessive spinocerebellar ataxia 20. Frontiers in Genetics, Sep 2020. URL: https://doi.org/10.3389/fgene.2020.01038, doi:10.3389/fgene.2020.01038. This article has 8 citations and is from a peer-reviewed journal.

10. (kim2021twokoreansiblings pages 3-4): Ae Ryoung Kim, Jong-Mok Lee, Go Hun Seo, Sang In Lee, Hyunwoo Bae, and Yun Jeong Lee. Two korean siblings with autosomal recessive spinocerebellar ataxia 20 caused by homozygous variants in snx14. Journal of Genetic Medicine, 18:127-131, Dec 2021. URL: https://doi.org/10.5734/jgm.2021.18.2.127, doi:10.5734/jgm.2021.18.2.127. This article has 1 citations.

11. (bryant2018snx14mutationsaffect pages 1-2): Dale Bryant, Yang Liu, Sanchari Datta, Hanaa Hariri, Marian Seda, Glenn Anderson, Emma Peskett, Charalambos Demetriou, Sergio Sousa, Dagan Jenkins, Peter Clayton, Maria Bitner-Glindzicz, Gudrun E Moore, W Mike Henne, and Philip Stanier. Snx14 mutations affect endoplasmic reticulum-associated neutral lipid metabolism in autosomal recessive spinocerebellar ataxia 20. Human Molecular Genetics, 27:1927–1940, Jun 2018. URL: https://doi.org/10.1093/hmg/ddy101, doi:10.1093/hmg/ddy101. This article has 82 citations and is from a domain leading peer-reviewed journal.

12. (zhang2021snx14deficiencyinduceddefective pages 8-9): Hongfeng Zhang, Yujuan Hong, Weijie Yang, Ruimin Wang, Ting Yao, Jian Wang, Ke Liu, Huilong Yuan, Chaoqun Xu, Yuanyuan Zhou, Guanxian Li, Lishan Zhang, Hong Luo, Xian Zhang, Dan Du, Hao Sun, Qiuyang Zheng, Yun-Wu Zhang, Yingjun Zhao, Ying Zhou, Huaxi Xu, and Xin Wang. Snx14 deficiency-induced defective axonal mitochondrial transport in purkinje cells underlies cerebellar ataxia and can be reversed by valproate. National Science Review, Feb 2021. URL: https://doi.org/10.1093/nsr/nwab024, doi:10.1093/nsr/nwab024. This article has 29 citations and is from a peer-reviewed journal.

13. (zhang2021snx14deficiencyinduceddefective pages 12-12): Hongfeng Zhang, Yujuan Hong, Weijie Yang, Ruimin Wang, Ting Yao, Jian Wang, Ke Liu, Huilong Yuan, Chaoqun Xu, Yuanyuan Zhou, Guanxian Li, Lishan Zhang, Hong Luo, Xian Zhang, Dan Du, Hao Sun, Qiuyang Zheng, Yun-Wu Zhang, Yingjun Zhao, Ying Zhou, Huaxi Xu, and Xin Wang. Snx14 deficiency-induced defective axonal mitochondrial transport in purkinje cells underlies cerebellar ataxia and can be reversed by valproate. National Science Review, Feb 2021. URL: https://doi.org/10.1093/nsr/nwab024, doi:10.1093/nsr/nwab024. This article has 29 citations and is from a peer-reviewed journal.

14. (shao2024compoundheterozygousmutation pages 1-2): Yuqi Shao, Saisai Yang, Jiafu Li, Lin Cheng, Jiawei Kang, Juan Liu, Jianhong Ma, Jie Duan, and Yuanzhen Zhang. Compound heterozygous mutation of the snx14 gene causes autosomal recessive spinocerebellar ataxia 20. Frontiers in Genetics, Apr 2024. URL: https://doi.org/10.3389/fgene.2024.1379366, doi:10.3389/fgene.2024.1379366. This article has 2 citations and is from a peer-reviewed journal.

15. (fenn2016genomesequencingreveals pages 1-2): Joe Fenn, Mike Boursnell, Rebekkah J. Hitti, Christopher A. Jenkins, Rebecca L. Terry, Simon L. Priestnall, Patrick J. Kenny, Cathryn S. Mellersh, and Oliver P. Forman. Genome sequencing reveals a splice donor site mutation in the snx14 gene associated with a novel cerebellar cortical degeneration in the hungarian vizsla dog breed. BMC Genetics, Aug 2016. URL: https://doi.org/10.1186/s12863-016-0433-y, doi:10.1186/s12863-016-0433-y. This article has 22 citations.

16. (kim2021twokoreansiblings pages 4-5): Ae Ryoung Kim, Jong-Mok Lee, Go Hun Seo, Sang In Lee, Hyunwoo Bae, and Yun Jeong Lee. Two korean siblings with autosomal recessive spinocerebellar ataxia 20 caused by homozygous variants in snx14. Journal of Genetic Medicine, 18:127-131, Dec 2021. URL: https://doi.org/10.5734/jgm.2021.18.2.127, doi:10.5734/jgm.2021.18.2.127. This article has 1 citations.

17. (zhou2024alteredlipidhomeostasis pages 17-18): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

18. (zhou2024alteredlipidhomeostasis media 516308f2): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

19. (zhou2024alteredlipidhomeostasis media 2328fed7): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

20. (zhou2024alteredlipidhomeostasis media 36ea72c9): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

21. (zhou2024alteredlipidhomeostasis media 6cd7fcc8): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

22. (zhou2024alteredlipidhomeostasis media 28783b99): Yijing Zhou, Vanessa B. Sanchez, Peining Xu, Thomas Roule, Marco Flores-Mendez, Brianna Ciesielski, Donna Yoo, Hiab Teshome, Teresa Jimenez, Shibo Liu, Mike Henne, Tim O’Brien, Ye He, Clementina Mesaros, and Naiara Akizu. Altered lipid homeostasis is associated with cerebellar neurodegeneration in snx14 deficiency. JCI Insight, Apr 2024. URL: https://doi.org/10.1172/jci.insight.168594, doi:10.1172/jci.insight.168594. This article has 7 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00